A Phase 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination with Cytarabine with Subsequent Combination Phase 2 Cohorts for Subjects with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)


Phase 1: Determine the maximum tolerated dose (MTD) of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS. Phase 2: Determine the overall response rate of OXi4503 in combination with intermediate-dose cytarabine in 1) subjects with MDS after failure of 1 prior hypomethylating agent and 2) subjects with relapsed and refractory AML after treatment failure of up to 1 prior chemotherapy regimen

Inclusion Criteria:

  1. Provide informed consent
  2. ≥ 18 years of age
  3. Phase 1 (dose escalation) subjects must have either:

    • AML that has failed to achieve complete remission or morphologic complete remission or
    • MDS - Marrow blasts must be > 5% and disease failed at least 1 prior hypomethylating agent
  4. Phase 2 (expansion) subjects must have either MDS or relapsed/refractory AML
  5. Eastern Cooperative Oncology Group performance status 0, 1, or 2
  6. Total bilirubin ≤ 2
  7. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times upper limit of normal (ULN)
  8. Serum creatinine < 2.5 times ULN
  9. Prothrombin time (PT)/international normalized ratio and (PTT) in normal range ± 25%
  10. Women of child-bearing potential
  11. Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods

Exclusion Criteria:

  1. Acute promyelocytic leukemia
  2. Absolute peripheral blood myeloblast count greater than 20,000/mm3
  3. Uncontrolled hypertension
  4. History of congenital long QT syndrome or torsades de pointes
  5. Pathologic bradycardia or heart block
  6. Prolonged baseline QTc
  7. Hiistory of ventricular arrhythmia
  8. Myocardial infarction and/or new ST elevation
  9. Any history of hemorrhagic stroke
  10. Symptomatic congestive heart failure
  11. Major hemorrhagic event within 28 days
  12. Suggestive central nervous system involvement with leukemia
  13. Any open wound
  14. Pregnant and nursing subjects are excluded
  15. Treatment with any anticancer therapy
  16. Treatment with colchicine is excluded.
  17. Psychiatric disorders that would interfere with consent


Acute myeloid leukemia, Myelodysplastic Syndromes (MDS), maximum tolerated dose, chemotherapy, cancer

Principal Investigator

Christopher R Cogle, M.D.



Contact Information


(352) 273-7493

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams